A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refracto...
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
About this item
Full title
Author / Creator
Ryan, Christine E. , Brander, Danielle M. , Barr, Paul M. , Tyekucheva, Svitlana , Hackett, Liam R. , Collins, Mary C. , Fernandes, Stacey M. , Ren, Yue , Zhou, Yinglu , McDonough, Mikaela M. , Walker, Heather A. , McEwan, Monica R. , Abramson, Jeremy S. , Jacobsen, Eric D. , LaCasce, Ann S. , Fisher, David C. , Brown, Jennifer R. and Davids, Matthew S.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
This study investigated ibrutinib plus obinutuzumab in relapsed/refractory CLL, evaluating tolerability of 3 sequencing regimens as well as overall safety and efficacy. Fifty-two patients were initially randomized 1:1:1 to receive either obinutuzumab 1 month before ibrutinib initiation, ibrutinib 1 month prior to obinutuzumab initiation, or to star...
Alternative Titles
Full title
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
Authors, Artists and Contributors
Author / Creator
Brander, Danielle M.
Barr, Paul M.
Tyekucheva, Svitlana
Hackett, Liam R.
Collins, Mary C.
Fernandes, Stacey M.
Ren, Yue
Zhou, Yinglu
McDonough, Mikaela M.
Walker, Heather A.
McEwan, Monica R.
Abramson, Jeremy S.
Jacobsen, Eric D.
LaCasce, Ann S.
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2771333851
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2771333851
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/s41375-023-01830-2
